Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Malignant thymoma: current status and future directions.

¹Division of Hematology-Oncology, University of California Davis Cancer Center, 4501 X Street, Sacramento, CA, 95817, USA. primo.lara@ucdmc.ucdavis.edu

Cancer Treatment Reviews

|April 22, 2000

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.

Cancer treatment and research communications·2019

Same author

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Same author

Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients.

Prostate cancer and prostatic diseases·2015

Same author

The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.

The pharmacogenomics journal·2014

Same author

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.

Oncogene·2014

Same author

The hazards of randomized phase II trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2011

Malignant thymomas are rare mediastinal tumors. Diagnosis and staging occur during surgery, with prognosis depending on disease stage, and treatment involving surgery, radiation, and chemotherapy.

Area of Science:

Oncology
Thoracic Surgery

Background:

Malignant thymomas are rare, indolent tumors originating in the anterior superior mediastinum.
Despite a benign histologic appearance, these tumors can invade locally or metastasize.
Patients may be asymptomatic or present with paraneoplastic syndromes like myasthenia gravis.

Purpose of the Study:

To review the diagnosis, staging, and treatment of malignant thymomas.
To highlight the importance of surgical staging and multimodality treatment approaches.

Main Methods:

Review of current literature on thymoma diagnosis and management.
Analysis of staging systems and treatment outcomes.
Discussion of therapeutic options including surgery, radiation, and chemotherapy.

Related Experiment Videos

Main Results:

Thymomas are staged as non-invasive or invasive, with prognosis correlating with stage.
Surgery is the primary curative treatment for early-stage disease.
Radiation and chemotherapy are effective for advanced, recurrent, or metastatic thymoma.

Conclusions:

Multicenter clinical trials are essential for evaluating novel therapies in thymoma.
Optimizing patient resources requires collaborative research efforts for this uncommon malignancy.